<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="publisher-id">JCBN</journal-id><journal-title-group><journal-title>Journal of Clinical Biochemistry and Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0912-0009</issn><issn pub-type="epub">1880-5086</issn><publisher><publisher-name>the Society for Free Radical Research Japan</publisher-name><publisher-loc>Kyoto, Japan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22962526</article-id><article-id pub-id-type="pmc">3432818</article-id><article-id pub-id-type="publisher-id">jcbnD-11-00017</article-id><article-id pub-id-type="doi">10.3164/jcbn.D-11-00017</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of astaxanthin-rich <italic>Haematococcus pluvialis</italic> extract on cognitive function: a randomised, double-blind, placebo-controlled study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Katagiri</surname><given-names>Mikiyuki</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Satoh</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tsuji</surname><given-names>Shinji</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shirasawa</surname><given-names>Takuji</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Aging Control, Graduate School of Medicine, Juntendo University, 3-3-10-201 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan</aff><aff id="aff2"><label>2</label>Technology Center, Yamaha Motor Co., Ltd., 3622-8 Nishikaizuka, Iwata, Shizuoka 438-0026, Japan</aff><author-notes><corresp id="cor1">*To whom correspondence should be addressed. E-mail: <email>mkatagi@juntendo.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>30</day><month>3</month><year>2012</year></pub-date><volume>51</volume><issue>2</issue><fpage>102</fpage><lpage>107</lpage><history><date date-type="received"><day>8</day><month>11</month><year>2011</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 JCBN</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>In this study we tried to confirm the effect of an astaxanthin-rich <italic>Haematococcus pluvialis</italic> extract on cognitive function in 96 subjects by a randomised double-blind placebo-controlled study. Healthy middle-aged and elderly subjects who complained of age-related forgetfulness were recruited. Ninety-six subjects were selected from the initial screen, and ingested a capsule containing astaxanthin-rich <italic>Haematococcus pluvialis</italic> extract, or a placebo capsule for 12 weeks. Somatometry, haematology, urine screens, and CogHealth and Groton Maze Learning Test were performed before and after every 4 weeks of administration. Changes in cognitive performance and the safety of astaxanthin-rich <italic>Haematococcus pluvialis</italic> extract administration were evaluated. CogHealth battery scores improved in the high-dosage group (12&#x000a0;mg astaxanthin/day) after 12 weeks. Groton Maze Learning Test scores improved earlier in the low-dosage (6&#x000a0;mg astaxanthin/day) and high-dosage groups than in the placebo group. The sample size, however, was small to show a significant difference in cognitive function between the astaxanthin-rich <italic>Haematococcus pluvialis</italic> extract and placebo groups. No adverse effect on the subjects was observed throughout this study. In conclusion, the results suggested that astaxanthin-rich <italic>Haematococcus pluvialis</italic> extract improves cognitive function in the healthy aged individuals.</p></abstract><kwd-group><kwd>Astaxanthin</kwd><kwd><italic>Haematococcus pluvialis</italic></kwd><kwd>cognitive function</kwd><kwd>aging</kwd><kwd>clinical efficacy</kwd></kwd-group></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><p>It is widely accepted that cognitive function decreases with aging. Moreover, dementia, Alzheimer disease, etc., are diseases in which cognitive function is drastically reduced.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup> Astaxanthin (Ax) is a carotenoid found in marine organisms such as shrimp, crab, krill, salmon, and microalgae.<sup>(<xref rid="B2" ref-type="bibr">2</xref>)</sup> It has strong anti-oxidant properties, as it consumes free radicals such as singlet oxygen to form stable triplet oxygen. In recent years, the effect of Ax against aging and against illnesses related to oxidisation stress has been confirmed by its use in cosmetics and whitening products and in the treatment of fatigue and cancer.<sup>(<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>)</sup> Ax exhibits immunomodulation properties;<sup>(<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>)</sup> alleviates eye fatigue;<sup>(<xref rid="B7" ref-type="bibr">7</xref>)</sup> and prevents <italic>Helicobacter pylori</italic> infection,<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup> metabolic syndrome,<sup>(<xref rid="B9" ref-type="bibr">9</xref>)</sup> and atopic dermatitis.<sup>(<xref rid="B10" ref-type="bibr">10</xref>)</sup></p><p>Due to its high consumption of glucose and oxygen, the brain tends to produce active oxygen and free radicals even though it is composed of substances that are easily oxidisable, such as unsaturated fatty acids and catecholamine. That is, the brain is an organ that is easily damaged by oxidisation stress. Brain health, such as that during normal aging and in neurodegenerative conditions such as Alzheimer disease or Parkinson disease, is closely related to oxidisation stress.<sup>(<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>)</sup> Halliwell reported oxidative damage in the aging brain, and suggested that anti-oxidants may play a role in protecting the brain from reactive oxygen species (ROS).<sup>(<xref rid="B13" ref-type="bibr">13</xref>)</sup></p><p>Therefore, since Ax is a strong antioxidant, we anticipate that it will be beneficial for maintaining brain health. Ax improved cell survival and reduced apoptosis and caspase 3 and 9 activation in neuroblastoma cells exposed to oxidative stress. Ax also inhibits oxidation stress-induced apoptosis in nerve cells. Memory and learning ability, as assessed in the T-maze test, is improved in immature mice by treatment with Ax. Moreover, when a normal aging mouse was medicated with Ax, memory improvement was observed. In Morris water maze examinations in Fischer rats, Ax treatment improved the memory of both immature (4 months) and aged rats (18 months). The effect was more remarkable in the old rats than in the young ones, suggesting that Ax improves cognition and/or prevents age-related cognitive damage.</p><p>We performed a preliminary clinical trial of 12 weeks of astaxanthin-rich <italic>Haematococcus pluvialis</italic> extract (Ax-Hp) treatment in 10 healthy men between 50 to 69 years of age, who complaints of age-related forgetfulness to assess the effects of the supplements on cognition.<sup>(<xref rid="B14" ref-type="bibr">14</xref>)</sup> We reported changes in the P300 brain waves, related to cognitive function, and improvements in CogHealth scores.<sup>(<xref rid="B14" ref-type="bibr">14</xref>)</sup> This randomised double-blind placebo-controlled study was performed to validate the effects of Ax-Hp on cognitive function. In the preliminary trial, a 12-mg/day dose of Ax elicited an effect. In this trial, we employed a 12-mg/day dose and a 6-mg/day dose to look for the presence of a dose response.</p></sec><sec sec-type="materials and methods"><title>Materials and Methods</title><sec><title>Study subjects</title><p>Healthy men and women between 45 to 64 years of age, who complaints of age-related forgetfulness were recruited; 138 subjects participated after providing signed informed consent. The subjects&#x02019; height, body weight, body mass index (BMI), blood pressure, and pulse rate were measured, along with performing haematological and urinary analyses, the Hachinski Ischaemic Scale, and tests of cognitive function (Hasegawa Dementia Scale-Revised [HDS-R], CogHealth, and Groton Maze Learning Test [GMLT]).</p><p>Subjects were excluded if they exhibited signs of dementia (HDS-R score, &#x02a7d;20 points) or cerebrovascular dementia (Hachinski Ischaemic Score, &#x02a7e;7), habitually consumed Ax supplements, used games and books designed to improve cognitive function, or were judged unfit for participation due to the results of their laboratory analyses. Eventually, 96 subjects (46 men and 50 women, 55.7&#x000a0;&#x000b1;&#x000a0;3.7 years of age) qualified for participation.</p></sec><sec><title>Study design</title><p>This randomised double-blind placebo-controlled study consisted of a high-dosage group (12&#x000a0;mg/day of Ax), low-dosage group (6&#x000a0;mg/day of Ax), and a placebo group. The subjects were randomly allocated into 3 groups (<italic>n</italic>&#x000a0;=&#x000a0;32 per group). After confirming that the average age and BMI of each group were equivalent, the study coordinator named the 3 groups as the high-dosage group, low-dosage group, and placebo group, and created the allocation table. The coordinator also labelled the high-dosage, low-dosage, and placebo supplements with the subject IDs, according to the allocation table. The coordinator sealed and stored the allocation table until the study ended. The demographic characteristics of each group are shown in Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>.</p><p>To minimise the learning effect, the CogHealth battery and GMLT were repeated 2 weeks after the screening tests; these scores were set as the baseline. Assessments of subjective symptoms, somatometry, haematological and urinary tests, and cognitive function tests (CogHealth and GMLT) were performed after 4, 8, and 12 weeks of Ax-Hp administration. The subjects maintained a diary to record their daily Ax-Hp supplement doses and the subjective symptoms during the 12-week study period (Fig.&#x000a0;<xref ref-type="fig" rid="F1">1</xref>).</p></sec><sec><title>Supplements</title><p>Puresta&#x000ae; (YAMAHA Motor Co., Ltd.)<sup>(<xref rid="B15" ref-type="bibr">15</xref>)</sup> was used for Ax-rich <italic>Haematococcus pluvialis</italic> oil. The raw materials of the supplements were olive oil (K. Kobayashi &#x00026; Co., Ltd.), gelatine (porcine in origin), Ax-Hp (6 or 12&#x000a0;mg of Ax dialcohol), glycerine, vitamin E, and an emulsifier. The placebo capsule had corn oil (J-OIL MILLS, Inc.) as a substitute for Ax-Hp. The subjects ingested the supplement after breakfast everyday for 12 weeks. When they could not take the supplement after breakfast, they were asked to take it after lunch or supper.</p></sec><sec><title>Ethics</title><p>The study protocol and informed consent documents were reviewed and approved by the ethics committee of Anti-Aging Science, Inc. All study subjects provided written informed consent prior to participation. The protocols were carried out under the provisions of the Declaration of Helsinki.</p></sec><sec><title>Cognitive function tests</title><sec><title>CogHealth battery</title><p>The CogHealth battery measures response time and accuracy with 5 card games played on a personal computer. The card games include tests of &#x02019;simple reaction&#x02019;, &#x02019;choice reaction&#x02019;, &#x02019;working memory&#x02019;, &#x02019;delayed recall&#x02019;, and &#x02019;divided attention&#x02019;. The &#x02019;simple reaction&#x02019; task requires the subjects to push a button as quickly as possible when the cards are placed face-up on a table. The &#x02019;choice reaction&#x02019; task requires subjects to identify whether a card is red or black by pushing a button (labelled YES or NO) when cards are placed face-up on a table. These tasks measure the reaction and control in a frontal lobe function. The &#x02019;working memory&#x02019; task requires subjects to identify whether a card is the same or different from the previous card. The &#x02019;delayed recall&#x02019; task requires subjects to identify whether overturned cards have appeared previously. These 2 tasks measure immediate memory and episodic memory. The &#x02019;divided attention&#x02019; task requires subjects to identify whether a card touches a line while moving up and down at random. This task measures spatial attention.</p><p>The response time is measured with a sensitivity of 1/1,000&#x000a0;s. The CogHealth battery is not influenced by culture, language, or level of education,<sup>(<xref rid="B16" ref-type="bibr">16</xref>)</sup> and is not influenced by the learning effect. Moreover, it can detect a slight change in cognitive function and can be used to diagnose mild cognitive impairment.<sup>(<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>)</sup></p><p>The CogHealth battery is based on task switching as an evaluation of high-order cognitive functions (execution function), such as control of action or reconstruction of information processing.<sup>(<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>)</sup> Moreover, brain image analysis by fMRI has revealed frontal lobe activity associated with task switching; thus, the CogHealth test is also a frontal lobe function test.<sup>(<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>)</sup></p><p>Reaction time in a task-switching test is a measure of the processing time in total cognition and performance processing, and is widely used as an index of cognitive information-processing ability.</p><p>Although CogHealth battery was developed in Australia, it has been validated in Japanese subjects.<sup>(<xref rid="B24" ref-type="bibr">24</xref>)</sup> A Japanese version of the CogHealth battery and the GMLT were offered with the cooperation of Health Solution, Inc. (Tokyo).</p><p>The subjects performed the CogHealth battery with a keypad that consists of only 2 keys to exclude the influence of computer skills. Prior to performing each task, the subjects received a full explanation of the task and were permitted to practice.</p><p><italic>GMLT</italic>. The &#x02019;maze&#x02019; of the GMLT was specified at random on a personal computer in a 10&#x000a0;&#x000d7;&#x000a0;10 layout requiring 28 steps to move from the upper left to the lower right goal.<sup>(<xref rid="B25" ref-type="bibr">25</xref>)</sup> The subjects worked through the same hidden maze 5 times, and then performed 5 CogHealth tasks. The same maze was performed once again at the end of testing, to provide a measure of spatial working memory. The GMLT indicates a learning effect, while the CogHealth is not affected by learning.</p><p>In order to exclude the influence of computer skills, the subjects performed the test on a touch screen. The subjects received instructions for all tasks of CogHealth battery and GMLT, were asked to &#x02019;Please push a button quickly and correctly&#x02019;, and were guided so that maximum performance might be demonstrated.<sup>(<xref rid="B26" ref-type="bibr">26</xref>)</sup></p><p>Analysis of the results of CogHealth battery included mean response time (ms) for every task, mean accuracy (%) of &#x02019;working memory&#x02019; and &#x02019;delayed recall&#x02019;, and those of the results of the GMLT included mean total duration (s) and total errors after performing a maze 6 times.</p></sec></sec><sec><title>Somatometry</title><p>Somatometry data included height, body weight, BMI, blood pressure (systolic/diastolic), and pulse rate.</p></sec><sec><title>Haematological and urinary tests</title><p>Haematological parameters, including white blood cell count, red blood cell count, haemoglobin level, haematocrit, platelet count, MCV, MCH, and MCHC; biochemical parameters, including levels of total protein, albumin, total bilirubin, triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, BUN, creatinine, AST, ALT, &#x003b3;-GTP, LDH, ALP, uric acid, serum electrolytes (Na, K, and Cl), and fasting blood sugar and A/G ratio; and qualitative urinalysis parameters, including protein, glucose, occult blood, pH, and urobilinogen, were determined.</p></sec><sec><title>Statistical analysis</title><p>All cognitive parameters of CogHealth and GMLT were compared between groups with 2-way factorial ANOVA adjusted for age and sex. One-way repeated measure ANOVA, adjusted for age and sex, was used to compare scores at baseline and at after 4, 8, and 12 weeks; multiple comparisons were performed using Bonferroni correction.</p><p>All statistical analysis was performed using SPSS 16.0J for Windows (SPSS Japan Inc., Tokyo, Japan).</p></sec></sec><sec sec-type="results"><title>Results</title><p>The effectiveness and safety of Ax-Hp were evaluated in 89 subjects who participated in all tests (high-dosage group, 29; low-dosage group, 29; and placebo, 31). The subjects ingested 80% or more of the provided Ax-Hp supplements.</p><sec><title>Improvement of CogHealth score</title><p>Table&#x000a0;<xref ref-type="table" rid="T2">2</xref> shows the comparison of 3 groups at the time of Ax-Hp administration, and Table&#x000a0;<xref ref-type="table" rid="T3">3</xref> shows the mean response time of all 5 CogHealth tasks and the mean accuracy of 2 tasks&#x02014;&#x02019;working memory&#x02019; and &#x02019;delayed recall&#x02019;&#x02014;at baseline and at 4, 8, and 12 weeks of Ax-Hp administration. The 3 groups did not significantly differ. However, the changes in response time were as follows: in the high-dosage group, improvement trends were observed for &#x02019;choice reaction&#x02019; (451.1&#x000a0;&#x000b1;&#x000a0;56.7 vs 480.1&#x000a0;&#x000b1;&#x000a0;77.5), &#x02019;delayed recall&#x02019; (818.3&#x000a0;&#x000b1;&#x000a0;195.9 vs 880.1&#x000a0;&#x000b1;&#x000a0;189.4), and &#x02019;divided attention&#x02019; (385.3&#x000a0;&#x000b1;&#x000a0;72.5 vs 419.4&#x000a0;&#x000b1; 79.6), each <italic>p</italic> values &#x0003c;0.1 at 12 weeks, and &#x02019;working memory&#x02019; was significantly improved (609.2&#x000a0;&#x000b1;&#x000a0;123.5 vs 655.9&#x000a0;&#x000b1;&#x000a0;136.5; <italic>p</italic>&#x0003c;0.05) at 12 weeks; improvement trends were observed for &#x02019;working memory&#x02019; (644.6&#x000a0;&#x000b1;&#x000a0;124.7 vs 686.0&#x000a0;&#x000b1;&#x000a0;148.9; <italic>p</italic>&#x0003c;0.1) at 12 weeks in the placebo group and &#x02019;delayed recall&#x02019; (844.4&#x000a0;&#x000b1;&#x000a0;103.8 vs 912.2&#x000a0;&#x000b1;&#x000a0;145.6; <italic>p</italic>&#x0003c;0.1) at 8 weeks in the low-dosage group. &#x02019;Delayed recall&#x02019;, a measure of accuracy, significantly improved in the high-dosage group at 12 weeks (72.9&#x000a0;&#x000b1;&#x000a0;7.5 vs 67.3&#x000a0;&#x000b1;&#x000a0;11.8; <italic>p</italic>&#x0003c;0.05). The results of the CogHealth test suggest that 12 weeks of high-dose Ax-Hp administration improved cognitive function.</p></sec><sec><title>Improvement of GMLT score</title><p>Table&#x000a0;<xref ref-type="table" rid="T4">4</xref> shows the comparison of 3 groups at the time of Ax-Hp administration, and Table&#x000a0;<xref ref-type="table" rid="T5">5</xref> shows the total durations and errors of the 6 trials of GMLT at baseline and at 4, 8, and 12 weeks of Ax-Hp administration. There was no significant difference in the 3 groups. In each group, the total duration was significantly shortened at 8 weeks, but there was no difference between the groups.</p><p>However, the total errors in each group were as follows: the low-dose group showed significant improvement after 4 weeks (63.3&#x000a0;&#x000b1;&#x000a0;24.5 at Week 4, 61.3&#x000a0;&#x000b1;&#x000a0;21.6 at Week 8, and 57.3&#x000a0;&#x000b1;&#x000a0;20.7 at Week 12, each <italic>p</italic>&#x0003c;0.01 vs baseline; 79.9&#x000a0;&#x000b1;&#x000a0;31.0); the high-dose group also showed significant improvement after 4 weeks (68.9&#x000a0;&#x000b1;&#x000a0;33.9; <italic>p</italic>&#x0003c;0.05 at Week 4, and 60.8&#x000a0;&#x000b1;&#x000a0;24.5; <italic>p</italic>&#x0003c;0.01 at Week 8 and 60.6&#x000a0;&#x000b1;&#x000a0;25.1; <italic>p</italic>&#x0003c;0.01 at Week 12, each <italic>p</italic> values vs baseline; 83.0&#x000a0;&#x000b1;&#x000a0;36.9), whereas the placebo group showed significant improvement at 12 weeks (60.7&#x000a0;&#x000b1;&#x000a0;25.6 vs 74.3&#x000a0;&#x000b1;&#x000a0;22.9, <italic>p</italic>&#x0003c;0.01).</p><p>On the basis of these results, we conclude that short-term spatial working memory was improved by ingestion of 6&#x000a0;mg of Ax.</p></sec><sec><title>Safety evaluation of Ax-Hp</title><p>Somatometry, haematological and urinary tests, and an oral consultation after 12 weeks of Ax-Hp administration revealed no confirmed adverse effects, indicating that Ax-Hp supplementation is safe.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>There have been many reports of research on cognitive functional improvement in the fields of medicine, psychology, and exercise physiology. The aging population and the medical issues that accompany aging have raised concerns about cognitive function improvement. And it is hoped that prevention may be achieved via specific dietary changes; there have been promising reports on the effectiveness of docosahexaenoic acid,<sup>(<xref rid="B27" ref-type="bibr">27</xref>)</sup> arachidonic acid,<sup>(<xref rid="B28" ref-type="bibr">28</xref>)</sup>
<italic>Ginkgo biloba</italic>,<sup>(<xref rid="B29" ref-type="bibr">29</xref>)</sup>
<italic>Pinus radiata</italic> bark extract,<sup>(<xref rid="B30" ref-type="bibr">30</xref>)</sup> and acetic acid bacteria<sup>(<xref rid="B31" ref-type="bibr">31</xref>)</sup> in retarding cognitive function loss.</p><p>Ax is a strong anti-oxidant. Nakagawa <italic>et al.</italic><sup>(<xref rid="B32" ref-type="bibr">32</xref>)</sup> reported the anti-oxidant effect of Ax-Hp on phospholipid peroxidation in human erythrocytes. Iwabayashi <italic>et al.</italic><sup>(<xref rid="B33" ref-type="bibr">33</xref>)</sup> reported that Ax-Hp increases the biological anti-oxidants potential (BAP) in human. It is clear that the anti-oxidant activity of Ax-Hp is effective in human and animal studies. This study lets expect that Ax-Hp reduces oxidisation in the brain, leading to improved scores in tests of cognitive function.</p><p>Flavonoids are strong natural anti-oxidants like Ax, and they were thought to improve age-related cognitive decline. Youdim <italic>et&#x000a0;al.</italic><sup>(<xref rid="B34" ref-type="bibr">34</xref>)</sup> reported on the neuroprotective effects of dietary flavonoids <italic>in vivo</italic>. Pipingas <italic>et al.</italic><sup>(<xref rid="B30" ref-type="bibr">30</xref>)</sup> reported that flavonoid-rich <italic>P. radiata</italic> bark extract improved cognitive function in tests of immediate recognition and spatial working memory. It is thought that the brain and nervous oxidisation are improved by the anti-oxidant activity of flavonoids, as is the case with Ax-Hp.</p><p>We performed a preliminary clinical trial of Ax-Hp and cognitive function improvement in 10 healthy men between 50 to 69 years of age, who complained of age-related forgetfulness. We reported that the response time of 5 CogHealth tasks was significantly improved (<italic>p</italic>&#x0003c;0.05) and that the amplitude of P300 brain waves, which are related to cognitive function, tended to increase (<italic>p</italic>&#x0003c;0.1) after 12 weeks of Ax-Hp treatment.</p><p>This randomised double-blind placebo-controlled study was performed to validate the beneficial effects of Ax-Hp on cognitive function in human subjects. Based on the results of the preliminary study, the high dosage was set at 12&#x000a0;mg/day, and 6&#x000a0;mg/day was set as the low dosage in order to confirm the presence of a dose response. The administration period was set to 12 weeks as in the preliminary study. Brain function was assessed with the CogHealth test and GMLT, both of which can perform objective measures in a large number of subjects.</p><p>We failed to show a significant difference between groups in the CogHealth test. No differences were observed at any of the assessments (4, 8, or 12 weeks). In addition, there were no differences between the high-dosage, low-dosage, and placebo groups in the reaction time and accuracy of the task-switching test. However, we observed significant improvements in the high-dose group in the response time for 1 task and in the accuracy of 1 task, and improvement trends was observed in 3 tasks. We conclude that these significant differences and trends are indicative of the Ax-induced improvement in cognitive function.</p><p>GMLT also revealed no significant differences between groups. The total duration did not change between groups or over time. However, total error improved significantly by 4 weeks in the low-dosage and high-dosage groups in contrast to the placebo group, which showed significant improvement only at 12 weeks. These results also suggest the Ax-induced improvement in cognitive function.</p><p>Although improvements in the CogHealth test were observed only with a dose of 12&#x000a0;mg/day, GMLT scores were improved at 6&#x000a0;mg/day. This difference may be because the methods of measuring cognitive performance differ. The GMLT includes a test of spatial working memory that is highly sensitive, can be used to measure age-related reductions in cognitive function, and can detect the effect of a supplement or remedy. Further verification is required.</p><p>Although the tests employed by Pipingas <italic>et al.</italic><sup>(<xref rid="B30" ref-type="bibr">30</xref>)</sup> differ from the tests used in this study, immediate recognition is evaluated by the CogHealth test and spatial working memory is evaluated by the GMLT. The combination of these tasks may be useful to verify other supplements or remedies.</p><p>The CogHealth test revealed improvements in cognitive function with 12&#x000a0;mg/day Ax-Hp for 12 weeks. This supports the results of our preliminary clinical study. In particular, the improvement in response time, which is a measure of short-term memory, and in the accuracy of the &#x02019;delayed recall&#x02019; task was remarkable. Moreover, total errors in the GMLT, which is also associated with memory, showed significant improvement with 6 and 12&#x000a0;mg/day Ax-Hp.</p><p>However, significant differences between groups were not observed, possibly due to the small sample size. Moreover, the average age may have been too young to observe age-related cognitive decline. We plan to investigate this issue further.</p><p>We observed no adverse effects to express any concerns regarding the safety of Ax-Hp.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Dr. Y. Koga (Department of Neuropsychiatry, Kyorin University School of medicine) for planning the study design; R. Sakurai (Tokyo Metropolitan Institute of Gerontology) for data analysis.</p></ack><sec><title>Conflicts of Interests</title><p>This work was supported by a grant from Yamaha Motor Co., Ltd.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savla</surname><given-names>GN</given-names></name><name><surname>Palmer</surname><given-names>BW</given-names></name></person-group><article-title>Neuropsychology in Alzheimer&#x02019;s disease and other dementia research</article-title><source>Curr Opin Psychiatry</source><year>2005</year><volume>18</volume><fpage>621</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">16639085</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussein</surname><given-names>G</given-names></name><name><surname>Sankawa</surname><given-names>U</given-names></name><name><surname>Goto</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name></person-group><article-title>Astaxanthin, a carotenoid with potential in human health and nutrition</article-title><source>J Nat Prod</source><year>2006</year><volume>69</volume><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">16562856</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurihara</surname><given-names>H</given-names></name><name><surname>Koda</surname><given-names>H</given-names></name><name><surname>Asami</surname><given-names>S</given-names></name><name><surname>Kiso</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name></person-group><article-title>Contribution of the antioxidative property of astaxanthin to its protective effect on the promotion of cancer metastasis in mice treated with restraint stress</article-title><source>Life Sci</source><year>2002</year><volume>70</volume><fpage>2509</fpage><lpage>2520</lpage><pub-id pub-id-type="pmid">12173414</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Kawamori</surname><given-names>T</given-names></name><name><surname>Ohnishi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Suppression of azoxymethane-induced rat colon carcinogenesis by dietary administration of naturally occurring xanthophylls astaxanthin and canthaxanthin during the postinitiation phase</article-title><source>Carcinogenesis</source><year>1995</year><volume>16</volume><fpage>2957</fpage><lpage>2963</lpage><pub-id pub-id-type="pmid">8603470</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jyonouchi</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Mizokami</surname><given-names>M</given-names></name><name><surname>Gross</surname><given-names>MD</given-names></name></person-group><article-title>Effects of various carotenoids on cloned, effector-stage T-helper cell activity</article-title><source>Nutr Cancer</source><year>1996</year><volume>26</volume><fpage>313</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">8910913</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoud</surname><given-names>FF</given-names></name><name><surname>Haines</surname><given-names>DD</given-names></name><name><surname>Abul</surname><given-names>HT</given-names></name><name><surname>Abal</surname><given-names>AT</given-names></name><name><surname>Onadeko</surname><given-names>BO</given-names></name><name><surname>Wise</surname><given-names>JA</given-names></name></person-group><article-title><italic>In vitro</italic> effects of astaxanthin combined with ginkgolide B on T lymphocyte activation in peripheral blood mononuclear cells from asthmatic subjects</article-title><source>J Pharmacol Sci</source><year>2004</year><volume>94</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">14978350</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagaki</surname><given-names>Y</given-names></name><name><surname>Hayasaka</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Hayasaka</surname><given-names>Y</given-names></name><name><surname>Sanada</surname><given-names>M</given-names></name><name><surname>Uonomi</surname><given-names>T</given-names></name></person-group><article-title> Effects of astaxanthin on accommodation, critical flicker fusion, and pattern visual evoked potential in visual display terminal workers</article-title><source>J Trad Med</source><year>2002</year><volume>19</volume><fpage>170</fpage><lpage>173</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Will&#x000e9;n</surname><given-names>R</given-names></name><name><surname>Wadstr&#x000f6;m</surname><given-names>T</given-names></name></person-group><article-title>Astaxanthin-rich algal meal and vitamin C inhibit <italic>Helicobacter pylori</italic> infection in BALB/cA mice</article-title><source>Antimicrob Agents Chemother</source><year>2000</year><volume>44</volume><fpage>2452</fpage><lpage>2457</lpage><pub-id pub-id-type="pmid">10952594</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchiyama</surname><given-names>A</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name></person-group><article-title>Clinical efficacy of astaxanthin-containing <italic>Haematococcus pluvialis</italic> extract for volunteers at-risk of metabolic syndrome</article-title><source>J Clin Biochem Nutr</source><year>2008</year><volume>43</volume><fpage>38</fpage><lpage>43</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>A</given-names></name><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Horibe</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of the intake of astaxanthin-containing <italic>Haematococcus pluvialis</italic> extract on the severity, immunofunction and physiological function in patients with atopic dermatitis</article-title><source>J Environ Dermatol Cutan Allergol</source><year>2009</year><volume>3</volume><fpage>429</fpage><lpage>438</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>Chan</surname><given-names>SL</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name></person-group><article-title>Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior</article-title><source>Physiol Rev</source><year>2002</year><volume>82</volume><fpage>637</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">12087131</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schon</surname><given-names>EA</given-names></name><name><surname>Manfredi</surname><given-names>G</given-names></name></person-group><article-title>Neuronal degeneration and mitochondrial dysfunction</article-title><source>J Clin Invest</source><year>2003</year><volume>111</volume><fpage>303</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">12569152</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B</given-names></name></person-group><article-title>Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment</article-title><source>Drugs Aging</source><year>2001</year><volume>18</volume><fpage>685</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">11599635</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>A</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Preliminary clinical evaluation of toxicity and efficacy of a new astaxanthin-rich <italic>Haematococcus pluvialis</italic> extract</article-title><source>J Clin Biochem Nutr</source><year>2009</year><volume>44</volume><fpage>280</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">19430618</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>A</given-names></name><name><surname>Ishikura</surname><given-names>M</given-names></name><name><surname>Murakami</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>D</given-names></name></person-group><article-title>The innovation of technology for microalgae cultivation and its application in functional foods and the nutraceutical industry</article-title><person-group person-group-type="editor"><name><surname>Bagchi</surname><given-names>D</given-names></name><name><surname>Lau</surname><given-names>FC</given-names></name><name><surname>Ghosh</surname><given-names>DK</given-names></name></person-group><source>Biotechnology in Functional Foods and Nutraceuticals</source><publisher-loc>London</publisher-loc><publisher-name>Taylor &#x00026; Francis Group, CRC Press</publisher-name><year>2010</year><fpage>313</fpage><lpage>329</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cairney</surname><given-names>S</given-names></name><name><surname>Clough</surname><given-names>AR</given-names></name><name><surname>Maruff</surname><given-names>P</given-names></name><name><surname>Collie</surname><given-names>A</given-names></name><name><surname>Currie</surname><given-names>BJ</given-names></name><name><surname>Currie</surname><given-names>J</given-names></name></person-group><article-title>Saccade and cognitive function in chronic kava users</article-title><source>Neuropsychopharmacology</source><year>2003</year><volume>28</volume><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">12589393</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darby</surname><given-names>D</given-names></name><name><surname>Maruff</surname><given-names>P</given-names></name><name><surname>Collie</surname><given-names>A</given-names></name><name><surname>McStephen</surname><given-names>M</given-names></name></person-group><article-title>Mild cognitive impairment can be detected by multiple assessments in a single day</article-title><source>Neurology</source><year>2002</year><volume>59</volume><fpage>1042</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">12370459</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>A</given-names></name><name><surname>Sugimura</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>S</given-names></name></person-group><article-title>Detection of mild cognitive impairment by CogHealth</article-title><source>Jpn J Geriatric Psychiatry</source><year>2006</year><volume>17</volume><fpage>210</fpage><lpage>217</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cepeda</surname><given-names>NJ</given-names></name><name><surname>Kramer</surname><given-names>AF</given-names></name><name><surname>Gonzalez de Sather</surname><given-names>JC</given-names></name></person-group><article-title>Changes in executive control across the life span: examination of task-switching performance</article-title><source>Dev Psychol</source><year>2001</year><volume>37</volume><fpage>715</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">11552766</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>LC</given-names></name></person-group><article-title>The nature of switch cost: task set configuration or carry-over effect?</article-title><source>Brain Res Cogn Brain Res</source><year>2005</year><volume>22</volume><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">15653291</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>AF</given-names></name><name><surname>Hahn</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Ageing, fitness and neurocognitive function</article-title><source>Nature</source><year>1999</year><volume>400</volume><fpage>418</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">10440369</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dove</surname><given-names>A</given-names></name><name><surname>Pollmann</surname><given-names>S</given-names></name><name><surname>Schubert</surname><given-names>T</given-names></name><name><surname>Wiggins</surname><given-names>CJ</given-names></name><name><surname>von Cramon</surname><given-names>DY</given-names></name></person-group><article-title>Prefrontal cortex activation in task switching: an event-related fMRI study</article-title><source>Brain Res Cogn Brain Res</source><year>2000</year><volume>9</volume><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">10666562</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimberg</surname><given-names>DY</given-names></name><name><surname>Aguirre</surname><given-names>GK</given-names></name><name><surname>D&#x02019;Esposito</surname><given-names>M</given-names></name></person-group><article-title>Modulation of task-related neural activity in task-switching: an fMRI study</article-title><source>Brain Res Cogn Brain Res</source><year>2000</year><volume>10</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">10978708</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogata</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Motohashi</surname><given-names>N</given-names></name></person-group><article-title>Evaluation of reliability, validity and transportability of CogHealth</article-title><source>Jpn J of Cognitive Neuroscience</source><year>2008</year><volume>10</volume><fpage>119</fpage><lpage>120</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrzak</surname><given-names>RH</given-names></name><name><surname>Maruff</surname><given-names>P</given-names></name><name><surname>Snyder</surname><given-names>PJ</given-names></name></person-group><article-title>Convergent validity and effect of instruction modification on the Groton maze learning test: a new measure of spatial working memory and error monitoring</article-title><source>Int J Neurosci</source><year>2009</year><volume>119</volume><fpage>1137</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">19922344</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Woodworth</surname><given-names>RS</given-names></name></person-group><source>Experimental psychology</source><publisher-loc>New York</publisher-loc><publisher-name>Holt</publisher-name><year>1938</year></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamazaki</surname><given-names>T</given-names></name><name><surname>Thienprasert</surname><given-names>A</given-names></name><name><surname>Kheovichai</surname><given-names>K</given-names></name><name><surname>Samuhaseneetoo</surname><given-names>S</given-names></name><name><surname>Nagasawa</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name></person-group><article-title>The effect of docosahexaenoic acid on aggression in elderly Thai subjects&#x02014;a placebo-controlled double-blind study</article-title><source>Nutr Neurosci</source><year>2002</year><volume>5</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11929196</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotani</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>E</given-names></name><name><surname>Warashina</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction</article-title><source>Neurosci Res</source><year>2006</year><volume>56</volume><fpage>159</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">16905216</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>DO</given-names></name><name><surname>Scholey</surname><given-names>AB</given-names></name><name><surname>Wesnes</surname><given-names>KA</given-names></name></person-group><article-title>The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers</article-title><source>Psychopharmacology (Berl)</source><year>2000</year><volume>151</volume><fpage>416</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">11026748</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pipingas</surname><given-names>A</given-names></name><name><surname>Silberstein</surname><given-names>RB</given-names></name><name><surname>Vitetta</surname><given-names>L</given-names></name><etal/></person-group><article-title>Improved cognitive performance after dietary supplementation with a <italic>Pinus radiata</italic> bark extract formulation</article-title><source>Phytother Res</source><year>2008</year><volume>22</volume><fpage>1168</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">18683195</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukami</surname><given-names>H</given-names></name><name><surname>Tachimoto</surname><given-names>H</given-names></name><name><surname>Kishi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Continuous ingestion of acetic acid bacteria: effect on cognitive function in healthy middle-aged and elderly persons</article-title><source>Anti-Aging Medicine</source><year>2009</year><volume>6</volume><fpage>60</fpage><lpage>65</lpage></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>K</given-names></name><name><surname>Kiko</surname><given-names>T</given-names></name><name><surname>Miyazawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Antioxidant effect of astaxanthin on phospholipid peroxidation in human erythrocytes</article-title><source>Br J Nutr</source><year>2011</year><volume>105</volume><fpage>1563</fpage><lpage>1571</lpage><pub-id pub-id-type="pmid">21276280</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwabayashi</surname><given-names>M</given-names></name><name><surname>Fujioka</surname><given-names>N</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Efficacy and safety of eight-week treatment with astaxanthin in individuals screened for increased oxidative stress burden</article-title><source>Anti-Aging Medicine</source><year>2009</year><volume>6</volume><fpage>15</fpage><lpage>21</lpage></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youdim</surname><given-names>KA</given-names></name><name><surname>Spencer</surname><given-names>JP</given-names></name><name><surname>Schroeter</surname><given-names>H</given-names></name><name><surname>Rice-Evans</surname><given-names>C</given-names></name></person-group><article-title>Dietary flavonoids as potential neuroprotectants</article-title><source>Biol Chem</source><year>2002</year><volume>383</volume><fpage>503</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">12033439</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig.&#x000a0;1</label><caption><p>Flow diagram of the experimental design and procedure.</p></caption><graphic xlink:href="jcbnD-11-00017f01"/></fig><table-wrap id="T1" position="float"><label>Table&#x000a0;1</label><caption><p>Characteristics of study subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Placebo group<hr/></th><th align="center" rowspan="1" colspan="1">Ax-Hp low-dosage group<hr/></th><th align="center" rowspan="1" colspan="1">Ax-Hp high-dosage group<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. of subjects</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">32</td></tr><tr><td align="left" rowspan="1" colspan="1">No. of men/women</td><td align="center" rowspan="1" colspan="1">15/17</td><td align="center" rowspan="1" colspan="1">16/16</td><td align="center" rowspan="1" colspan="1">15/17</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">51.6&#x000a0;&#x000b1;&#x000a0;5.3</td><td align="center" rowspan="1" colspan="1">51.1&#x000a0;&#x000b1;&#x000a0;5.9</td><td align="center" rowspan="1" colspan="1">51.5&#x000a0;&#x000b1;&#x000a0;5.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">161.6&#x000a0;&#x000b1;&#x000a0;7.0</td><td align="center" rowspan="1" colspan="1">161.8&#x000a0;&#x000b1;&#x000a0;8.4</td><td align="center" rowspan="1" colspan="1">161.4&#x000a0;&#x000b1;&#x000a0;8.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Body weight (kg)</td><td align="center" rowspan="1" colspan="1">61.1&#x000a0;&#x000b1;&#x000a0;10.1</td><td align="center" rowspan="1" colspan="1">61.0&#x000a0;&#x000b1;&#x000a0;10.8</td><td align="center" rowspan="1" colspan="1">62.6&#x000a0;&#x000b1;&#x000a0;11.6</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI</td><td align="center" rowspan="1" colspan="1">23.3&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="center" rowspan="1" colspan="1">23.2&#x000a0;&#x000b1;&#x000a0;2.9</td><td align="center" rowspan="1" colspan="1">23.9&#x000a0;&#x000b1;&#x000a0;3.3</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table&#x000a0;2</label><caption><p>Comparison of the 3 groups of CogHealth at the time of Ax-Hp administration</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">Task</th><th colspan="3" align="center" rowspan="1"><italic>p</italic> value<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Time</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Interaction</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Response time</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Simple reaction</td><td align="center" rowspan="1" colspan="1">0.376</td><td align="center" rowspan="1" colspan="1">0.249</td><td align="center" rowspan="1" colspan="1">0.817</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Choice reaction</td><td align="center" rowspan="1" colspan="1">0.601</td><td align="center" rowspan="1" colspan="1">0.770</td><td align="center" rowspan="1" colspan="1">0.826</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Working memory</td><td align="center" rowspan="1" colspan="1">0.220</td><td align="center" rowspan="1" colspan="1">0.636</td><td align="center" rowspan="1" colspan="1">0.436</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Delayed recall</td><td align="center" rowspan="1" colspan="1">0.174</td><td align="center" rowspan="1" colspan="1">0.552</td><td align="center" rowspan="1" colspan="1">0.423</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Divided attention</td><td align="center" rowspan="1" colspan="1">0.621</td><td align="center" rowspan="1" colspan="1">0.467</td><td align="center" rowspan="1" colspan="1">0.810</td></tr><tr><td align="left" rowspan="1" colspan="1">Accuracy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Working memory</td><td align="center" rowspan="1" colspan="1">0.074</td><td align="center" rowspan="1" colspan="1">0.892</td><td align="center" rowspan="1" colspan="1">0.178</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Delayed recall</td><td align="center" rowspan="1" colspan="1">0.343</td><td align="center" rowspan="1" colspan="1">0.344</td><td align="center" rowspan="1" colspan="1">0.635</td></tr></tbody></table><table-wrap-foot><p>Dropouts were excluded from the data analysis. Data were analyzed by 2-way factorial ANOVA adjusted for age and sex.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table&#x000a0;3</label><caption><p>Mean response times and accuracies (&#x000b1;SD) on CogHealth tasks at baseline, and after 4, 8, and 12 weeks of Ax treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1">Group/Task</th><th align="center" rowspan="1" colspan="1">Baseline<hr/></th><th colspan="2" align="center" rowspan="1">4 weeks<hr/></th><th colspan="2" align="center" rowspan="1">8 weeks<hr/></th><th colspan="2" align="center" rowspan="1">12 weeks<hr/></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> (vs baseline)</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> (vs baseline)</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> (vs baseline)</th></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1">Placebo group (<italic>n</italic>&#x000a0;=&#x000a0;31)</td></tr><tr><td align="left" rowspan="1" colspan="1">Response time (ms)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Simple reaction</td><td align="center" rowspan="1" colspan="1">288.7&#x000a0;&#x000b1;&#x000a0;59.1</td><td align="center" rowspan="1" colspan="1">271.5&#x000a0;&#x000b1;&#x000a0;38.2</td><td align="center" rowspan="1" colspan="1">0.789</td><td align="center" rowspan="1" colspan="1">267.8&#x000a0;&#x000b1;&#x000a0;40.6</td><td align="center" rowspan="1" colspan="1">0.345</td><td align="center" rowspan="1" colspan="1">265.0&#x000a0;&#x000b1;&#x000a0;36.9</td><td align="center" rowspan="1" colspan="1">0.123</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Choice reaction</td><td align="center" rowspan="1" colspan="1">467.5&#x000a0;&#x000b1;&#x000a0;70.9</td><td align="center" rowspan="1" colspan="1">446.4&#x000a0;&#x000b1;&#x000a0;53.1</td><td align="center" rowspan="1" colspan="1">0.506</td><td align="center" rowspan="1" colspan="1">453.1&#x000a0;&#x000b1;&#x000a0;56.5</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">440.9&#x000a0;&#x000b1;&#x000a0;52.8</td><td align="center" rowspan="1" colspan="1">0.124</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Working memory</td><td align="center" rowspan="1" colspan="1">686.0&#x000a0;&#x000b1;&#x000a0;148.9</td><td align="center" rowspan="1" colspan="1">647.7&#x000a0;&#x000b1;&#x000a0;100.4</td><td align="center" rowspan="1" colspan="1">0.194</td><td align="center" rowspan="1" colspan="1">670.6&#x000a0;&#x000b1;&#x000a0;151.5</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">644.6&#x000a0;&#x000b1;&#x000a0;124.7</td><td align="center" rowspan="1" colspan="1">0.071<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Delayed recall</td><td align="center" rowspan="1" colspan="1">909.7&#x000a0;&#x000b1;&#x000a0;218.1</td><td align="center" rowspan="1" colspan="1">875.3&#x000a0;&#x000b1;&#x000a0;217.8</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">887.8&#x000a0;&#x000b1;&#x000a0;243.1</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">903.8&#x000a0;&#x000b1;&#x000a0;270.1</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Divided attention</td><td align="center" rowspan="1" colspan="1">413.0&#x000a0;&#x000b1;&#x000a0;103.3</td><td align="center" rowspan="1" colspan="1">390.0&#x000a0;&#x000b1;&#x000a0;75.2</td><td align="center" rowspan="1" colspan="1">0.597</td><td align="center" rowspan="1" colspan="1">379.6&#x000a0;&#x000b1;&#x000a0;82.0</td><td align="center" rowspan="1" colspan="1">0.153</td><td align="center" rowspan="1" colspan="1">388.7&#x000a0;&#x000b1;&#x000a0;73.9</td><td align="center" rowspan="1" colspan="1">0.397</td></tr><tr><td align="left" rowspan="1" colspan="1">Accuracy (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Working memory</td><td align="center" rowspan="1" colspan="1">95.1&#x000a0;&#x000b1;&#x000a0;5.3</td><td align="center" rowspan="1" colspan="1">96.2&#x000a0;&#x000b1;&#x000a0;3.8</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">95.2&#x000a0;&#x000b1;&#x000a0;5.5</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">94.9&#x000a0;&#x000b1;&#x000a0;8.3</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Delayed recall</td><td align="center" rowspan="1" colspan="1">66.9&#x000a0;&#x000b1;&#x000a0;10.3</td><td align="center" rowspan="1" colspan="1">68.8&#x000a0;&#x000b1;&#x000a0;8.6</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">71.1&#x000a0;&#x000b1;&#x000a0;10.4</td><td align="center" rowspan="1" colspan="1">0.355</td><td align="center" rowspan="1" colspan="1">69.2&#x000a0;&#x000b1;&#x000a0;9.4</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1">AX low-dosage group (<italic>n</italic>&#x000a0;=&#x000a0;29)</td></tr><tr><td align="left" rowspan="1" colspan="1">Response time (ms)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Simple reaction</td><td align="center" rowspan="1" colspan="1">303.4&#x000a0;&#x000b1;&#x000a0;81.7</td><td align="center" rowspan="1" colspan="1">284.3&#x000a0;&#x000b1;&#x000a0;46.2</td><td align="center" rowspan="1" colspan="1">0.660</td><td align="center" rowspan="1" colspan="1">274.8&#x000a0;&#x000b1;&#x000a0;39.4</td><td align="center" rowspan="1" colspan="1">0.077</td><td align="center" rowspan="1" colspan="1">285.0&#x000a0;&#x000b1;&#x000a0;48.0</td><td align="center" rowspan="1" colspan="1">0.608</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Choice reaction</td><td align="center" rowspan="1" colspan="1">468.0&#x000a0;&#x000b1;&#x000a0;82.6</td><td align="center" rowspan="1" colspan="1">448.8&#x000a0;&#x000b1;&#x000a0;60.4</td><td align="center" rowspan="1" colspan="1">0.558</td><td align="center" rowspan="1" colspan="1">440.2&#x000a0;&#x000b1;&#x000a0;52.9</td><td align="center" rowspan="1" colspan="1">0.080</td><td align="center" rowspan="1" colspan="1">446.7&#x000a0;&#x000b1;&#x000a0;44.0</td><td align="center" rowspan="1" colspan="1">0.393</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Working memory</td><td align="center" rowspan="1" colspan="1">661.9&#x000a0;&#x000b1;&#x000a0;120.2</td><td align="center" rowspan="1" colspan="1">651.4&#x000a0;&#x000b1;&#x000a0;94.2</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">629.6&#x000a0;&#x000b1;&#x000a0;96.4</td><td align="center" rowspan="1" colspan="1">0.352</td><td align="center" rowspan="1" colspan="1">641.6&#x000a0;&#x000b1;&#x000a0;91.8</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Delayed recall</td><td align="center" rowspan="1" colspan="1">912.2&#x000a0;&#x000b1;&#x000a0;145.6</td><td align="center" rowspan="1" colspan="1">882.3&#x000a0;&#x000b1;&#x000a0;139.5</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">844.4&#x000a0;&#x000b1;&#x000a0;103.8</td><td align="center" rowspan="1" colspan="1">0.051<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">878.4&#x000a0;&#x000b1;&#x000a0;131.4</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Divided attention</td><td align="center" rowspan="1" colspan="1">428.8&#x000a0;&#x000b1;&#x000a0;72.4</td><td align="center" rowspan="1" colspan="1">411.9&#x000a0;&#x000b1;&#x000a0;85.7</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">406.7&#x000a0;&#x000b1;&#x000a0;71.9</td><td align="center" rowspan="1" colspan="1">0.960</td><td align="center" rowspan="1" colspan="1">405.3&#x000a0;&#x000b1;&#x000a0;81.6</td><td align="center" rowspan="1" colspan="1">0.483</td></tr><tr><td align="left" rowspan="1" colspan="1">Accuracy (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Working memory</td><td align="center" rowspan="1" colspan="1">94.1&#x000a0;&#x000b1;&#x000a0;5.0</td><td align="center" rowspan="1" colspan="1">95.3&#x000a0;&#x000b1;&#x000a0;4.4</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">96.4&#x000a0;&#x000b1;&#x000a0;5.3</td><td align="center" rowspan="1" colspan="1">0.159</td><td align="center" rowspan="1" colspan="1">96.7&#x000a0;&#x000b1;&#x000a0;3.7</td><td align="center" rowspan="1" colspan="1">0.186</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Delayed recall</td><td align="center" rowspan="1" colspan="1">70.7&#x000a0;&#x000b1;&#x000a0;6.7</td><td align="center" rowspan="1" colspan="1">72.4&#x000a0;&#x000b1;&#x000a0;11.0</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">72.9&#x000a0;&#x000b1;&#x000a0;8.8</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">71.0&#x000a0;&#x000b1;&#x000a0;7.9</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1">AX high-dosage group (<italic>n</italic>&#x000a0;=&#x000a0;29)</td></tr><tr><td align="left" rowspan="1" colspan="1">Response time (ms)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Simple reaction</td><td align="center" rowspan="1" colspan="1">302.9&#x000a0;&#x000b1;&#x000a0;71.2</td><td align="center" rowspan="1" colspan="1">292.2&#x000a0;&#x000b1;&#x000a0;49.7</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">284.5&#x000a0;&#x000b1;&#x000a0;56.7</td><td align="center" rowspan="1" colspan="1">0.626</td><td align="center" rowspan="1" colspan="1">280.6&#x000a0;&#x000b1;&#x000a0;47.3</td><td align="center" rowspan="1" colspan="1">0.242</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Choice reaction</td><td align="center" rowspan="1" colspan="1">480.1&#x000a0;&#x000b1;&#x000a0;77.5</td><td align="center" rowspan="1" colspan="1">454.7&#x000a0;&#x000b1;&#x000a0;64.1</td><td align="center" rowspan="1" colspan="1">0.207</td><td align="center" rowspan="1" colspan="1">453.1&#x000a0;&#x000b1;&#x000a0;67.2</td><td align="center" rowspan="1" colspan="1">0.104</td><td align="center" rowspan="1" colspan="1">451.1&#x000a0;&#x000b1;&#x000a0;56.7</td><td align="center" rowspan="1" colspan="1">0.083<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Working memory</td><td align="center" rowspan="1" colspan="1">655.9&#x000a0;&#x000b1;&#x000a0;136.5</td><td align="center" rowspan="1" colspan="1">638.6&#x000a0;&#x000b1;&#x000a0;130.2</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">624.5&#x000a0;&#x000b1;&#x000a0;132.1</td><td align="center" rowspan="1" colspan="1">0.319</td><td align="center" rowspan="1" colspan="1">609.2&#x000a0;&#x000b1;&#x000a0;123.5</td><td align="center" rowspan="1" colspan="1">0.044*</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Delayed recall</td><td align="center" rowspan="1" colspan="1">880.1&#x000a0;&#x000b1;&#x000a0;189.4</td><td align="center" rowspan="1" colspan="1">843.9&#x000a0;&#x000b1;&#x000a0;182.8</td><td align="center" rowspan="1" colspan="1">0.852</td><td align="center" rowspan="1" colspan="1">829.4&#x000a0;&#x000b1;&#x000a0;209.8</td><td align="center" rowspan="1" colspan="1">0.302</td><td align="center" rowspan="1" colspan="1">818.3&#x000a0;&#x000b1;&#x000a0;195.9</td><td align="center" rowspan="1" colspan="1">0.097<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Divided attention</td><td align="center" rowspan="1" colspan="1">419.4&#x000a0;&#x000b1;&#x000a0;79.6</td><td align="center" rowspan="1" colspan="1">415.4&#x000a0;&#x000b1;&#x000a0;104.9</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">392.3&#x000a0;&#x000b1;&#x000a0;86.9</td><td align="center" rowspan="1" colspan="1">0.483</td><td align="center" rowspan="1" colspan="1">385.3&#x000a0;&#x000b1;&#x000a0;72.5</td><td align="center" rowspan="1" colspan="1">0.074<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Accuracy (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Working memory</td><td align="center" rowspan="1" colspan="1">95.4&#x000a0;&#x000b1;&#x000a0;5.8</td><td align="center" rowspan="1" colspan="1">93.8&#x000a0;&#x000b1;&#x000a0;6.6</td><td align="center" rowspan="1" colspan="1">0.433</td><td align="center" rowspan="1" colspan="1">95.4&#x000a0;&#x000b1;&#x000a0;5.5</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">95.6&#x000a0;&#x000b1;&#x000a0;7.4</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Delayed recall</td><td align="center" rowspan="1" colspan="1">67.3&#x000a0;&#x000b1;&#x000a0;11.8</td><td align="center" rowspan="1" colspan="1">71.3&#x000a0;&#x000b1;&#x000a0;9.0</td><td align="center" rowspan="1" colspan="1">0.361</td><td align="center" rowspan="1" colspan="1">71.5&#x000a0;&#x000b1;&#x000a0;7.3</td><td align="center" rowspan="1" colspan="1">0.320</td><td align="center" rowspan="1" colspan="1">72.9&#x000a0;&#x000b1;&#x000a0;7.5</td><td align="center" rowspan="1" colspan="1">0.028*</td></tr></tbody></table><table-wrap-foot><p>Dropouts were excluded from the data analysys. <sup>&#x02020;</sup><italic>p</italic>&#x0003c;0.1, *<italic>p</italic>&#x0003c;0.05, **<italic>p</italic>&#x0003c;0.01 (vs baseline). Data were analyzed by one-way repeated measure ANOVA, adjusted for age and sex. Multiple comparisons of 4, 8, and 12 weeks with baseline were performed using Bonferroni correction.</p></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table&#x000a0;4</label><caption><p>Comparison of the 3 groups of GMLT at the time of Ax-Hp administration</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1">Task</th><th colspan="3" align="center" rowspan="1"><italic>p</italic> value<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Time</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Interaction</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Total duration</td><td align="center" rowspan="1" colspan="1">0.185</td><td align="center" rowspan="1" colspan="1">0.850</td><td align="center" rowspan="1" colspan="1">0.870</td></tr><tr><td align="center" rowspan="1" colspan="1">Total errors</td><td align="center" rowspan="1" colspan="1">0.724</td><td align="center" rowspan="1" colspan="1">0.905</td><td align="center" rowspan="1" colspan="1">0.278</td></tr></tbody></table><table-wrap-foot><p>Dropouts were excluded from the data analysys. Data were analyzed by 2-way factorial ANOVA adjusted for age and sex.</p></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table&#x000a0;5</label><caption><p>Mean total duration and total errors (&#x000b1;SD) on GMLT tasks at baseline, and after 4, 8, and 12 weeks of Ax treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" colspan="1">Group/Task</th><th align="center" rowspan="1" colspan="1">Baseline<hr/></th><th colspan="2" align="center" rowspan="1">4 weeks<hr/></th><th colspan="2" align="center" rowspan="1">8 weeks<hr/></th><th colspan="2" align="center" rowspan="1">12 weeks<hr/></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> (vs baseline)</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> (vs baseline)</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean&#x000a0;&#x000b1;&#x000a0;SD</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> (vs baseline)</th></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1">Placebo group (<italic>n</italic>&#x000a0;=&#x000a0;31)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total duration (s)</td><td align="center" rowspan="1" colspan="1">158.8&#x000a0;&#x000b1;&#x000a0;36.0</td><td align="center" rowspan="1" colspan="1">148.7&#x000a0;&#x000b1;&#x000a0;35.6</td><td align="center" rowspan="1" colspan="1">0.193</td><td align="center" rowspan="1" colspan="1">143.0&#x000a0;&#x000b1;&#x000a0;34.9</td><td align="center" rowspan="1" colspan="1">0.017*</td><td align="center" rowspan="1" colspan="1">134.4&#x000a0;&#x000b1;&#x000a0;33.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001**</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total errors</td><td align="center" rowspan="1" colspan="1">74.3&#x000a0;&#x000b1;&#x000a0;22.9</td><td align="center" rowspan="1" colspan="1">67.8&#x000a0;&#x000b1;&#x000a0;23.3</td><td align="center" rowspan="1" colspan="1">0.925</td><td align="center" rowspan="1" colspan="1">65.1&#x000a0;&#x000b1;&#x000a0;23.0</td><td align="center" rowspan="1" colspan="1">0.258</td><td align="center" rowspan="1" colspan="1">60.7&#x000a0;&#x000b1;&#x000a0;25.6</td><td align="center" rowspan="1" colspan="1">0.003**</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1">Ax low-dosage group (<italic>n</italic>&#x000a0;=&#x000a0;29)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total duration (s)</td><td align="center" rowspan="1" colspan="1">157.8&#x000a0;&#x000b1;&#x000a0;25.9</td><td align="center" rowspan="1" colspan="1">147.3&#x000a0;&#x000b1;&#x000a0;21.5</td><td align="center" rowspan="1" colspan="1">0.322</td><td align="center" rowspan="1" colspan="1">137.2&#x000a0;&#x000b1;&#x000a0;23.8</td><td align="center" rowspan="1" colspan="1">0.002**</td><td align="center" rowspan="1" colspan="1">127.8&#x000a0;&#x000b1;&#x000a0;16.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001**</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total errors</td><td align="center" rowspan="1" colspan="1">79.9&#x000a0;&#x000b1;&#x000a0;31.0</td><td align="center" rowspan="1" colspan="1">63.3&#x000a0;&#x000b1;&#x000a0;24.5</td><td align="center" rowspan="1" colspan="1">0.005**</td><td align="center" rowspan="1" colspan="1">61.3&#x000a0;&#x000b1;&#x000a0;21.6</td><td align="center" rowspan="1" colspan="1">0.001**</td><td align="center" rowspan="1" colspan="1">57.3&#x000a0;&#x000b1;&#x000a0;20.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001**</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1">Ax high-dosage group (<italic>n</italic>&#x000a0;=&#x000a0;29)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total duration (s)</td><td align="center" rowspan="1" colspan="1">162.0&#x000a0;&#x000b1;&#x000a0;44.8</td><td align="center" rowspan="1" colspan="1">153.2&#x000a0;&#x000b1;&#x000a0;43.0</td><td align="center" rowspan="1" colspan="1">0.517</td><td align="center" rowspan="1" colspan="1">139.5&#x000a0;&#x000b1;&#x000a0;34.3</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001**</td><td align="center" rowspan="1" colspan="1">135.4&#x000a0;&#x000b1;&#x000a0;33.2</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001**</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total errors</td><td align="center" rowspan="1" colspan="1">83.0&#x000a0;&#x000b1;&#x000a0;36.9</td><td align="center" rowspan="1" colspan="1">68.9&#x000a0;&#x000b1;&#x000a0;33.9</td><td align="center" rowspan="1" colspan="1">0.024*</td><td align="center" rowspan="1" colspan="1">60.8&#x000a0;&#x000b1;&#x000a0;24.5</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001**</td><td align="center" rowspan="1" colspan="1">60.6&#x000a0;&#x000b1;&#x000a0;25.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001**</td></tr></tbody></table><table-wrap-foot><p>Dropouts were excluded from the data analysys. *<italic>p</italic>&#x0003c;0.05, **<italic>p</italic>&#x0003c;0.01 (vs baseline). Data were analyzed by one-way repeated measure ANOVA, adjusted for age and sex. Multiple comparisons of 4, 8, and 12 weeks with baseline were performed using Bonferroni correction.</p></table-wrap-foot></table-wrap></floats-group></article>